Lotte Biologics Completes 120,000-Liter Plant in Songdo International City... “Flexibility Is a Latecomer’s Weapon”
- Input
- 2026-11-18 16:34:34
- Updated
- 2026-11-18 16:34:34

Lotte Biologics held a completion ceremony for its first plant at the Songdo International City Bio Campus in Incheon on the 18th. Around 300 political and government figures attended, and Prime Minister Han Seong-suk sent a congratulatory message by video.
In his congratulatory remarks, Lotte Group Chairman Shin Dong-bin said, “The biotech business is a future growth engine for Lotte Group and a next-generation industry that will lead the next generation of the Republic of Korea.” He added, “I hope the first plant at the Songdo International City Bio Campus will be an important turning point that raises the competitiveness of Korea’s biotech industry to a new level.”
Shin attended the groundbreaking ceremony in July 2024 and personally visited the plant for the first time this July to review its order status, among other ways he has kept a close eye on the biotech business. Shin Yoo-yeol, CEO of Lotte Biologics, who was promoted to president of Lotte Corporation on the 16th, also said at the completion ceremony that day, “We will become a CDMO partner that grows alongside our customers.”
The completion of the first Songdo International City plant is significant because it fulfills the “acquisition and construction” strategy Lotte Biologics set out when it launched in 2022. The company entered the market by acquiring Bristol Myers Squibb’s (BMS) production facility in Syracuse, New York, at its launch, and four years later has built a large-scale commercial production base in Korea. This means it now has a “Korea-U.S. dual-site” system, with production bases in both the United States and Korea.
Construction of the first Songdo International City plant began in March 2024. It has a total floor area of approximately 99,558 square meters and production capacity of 120,000 liters. Along with eight 15,000-liter culture vessels, it operates a 3,000-liter bioreactor and small-scale culture equipment, allowing it to respond flexibly to customers’ production needs. The company has introduced an automated logistics warehouse and a laboratory information management system (LIMS). Its location near a biotech cluster and an international airport is also considered an advantage. The production-readiness stage (GMP Ready) was completed this month, six months ahead of the original target.
Lotte Biologics said it expects supply-chain restructuring driven by geopolitical uncertainty to accelerate. It added that it would leverage both its operational know-how in Syracuse and the tariff advantages of producing locally in the United States.
The company also highlighted its competitive strengths as a latecomer. Asked why customers would choose Lotte Biologics over Samsung Biologics, a Lotte Biologics representative said, “Samsung showed success first and demonstrated the strength of K-bio, and Lotte Biologics is also benefiting from that halo effect.” The representative added, “Just as customers once moved to Samsung after comparing it with global CDMO Lonza, we believe Lotte is now in that position.”
On this point, Jeon Ji-won, head of strategic planning, emphasized, “Customers don’t select a particular CDMO in advance and then outsource to it. They choose a provider that suits the scale of the drug under development and their development strategy, and sometimes divide the work among several providers.” Jeon added, “As a latecomer, we can better meet customers’ needs and proactively address their pain points.”
Lotte Biologics estimates that the first Songdo International City plant could generate approximately 700 billion won in annual revenue when operating at full capacity. The company aims to generate at least 1 trillion won in revenue by 2030 with the addition of its second and third plants, and is also pursuing entry into the capital markets. The first plant is scheduled to begin commercial production in 2027, after customer audits, technology transfer and process validation, and GMP inspections by regulatory authorities.
CEO James Park said, “We will carry over into the biotech business the service mindset and customer-first approach that Lotte Group has cultivated over many years.”
[email protected] Jung Sang-hee Reporter